In a SWOG Cancer Research Network trial that put three targeted drugs to the test, the small molecule inhibitor cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer – findings expected to change medical practice. These findings will be presented at ASCO’s virtual 2021 Genitourinary Cancers Symposium on Feb. 13, 2021
0 Comments
Masks help protect the people wearing them from getting or spreading SARS-CoV-2, the virus that causes COVID-19, but now researchers from the National Institutes of Health have added evidence for yet another potential benefit for wearers: The humidity created inside the mask may help combat respiratory diseases such as COVID-19. The study, led by researchers
0 Comments
DNA synthesis is one of the pillars of Covid-19 research that has suffered supply disruptions during lockdowns. Thomas Ybert, CEO of DNA Script, discusses the French company’s plans to protect research from future disruptions by giving every lab the ability to synthesize its own DNA molecules.  The Covid-19 pandemic has highlighted more than ever the
0 Comments
Standardized, carefully managed samples are indispensable for the success of any clinical study. Still, sample processing and management receive little attention. Clinical trials studying immuno-oncology treatments, auto-immune therapeutics, cell therapies, or gene therapies use sophisticated assays to identify and measure biomarkers, as well as the effects and side-effects of these novel therapies. These assays are
0 Comments
The EU imposed stringent controls on the commercialization of gene-edited food back in 2018. Years later, regulators are still working in the dark, with no established tests in place. The EU has some of the strictest food regulations in the world surrounding the cultivation and commercialization of genetically modified organisms (GMOs), which it defines as organisms whose
0 Comments
The recent approvals of long-acting HIV injections promise to lighten the load of HIV sufferers around the world. However, a vital UN deadline for improving global HIV healthcare has slipped away. At the end of January, ViiV Healthcare’s Cabenuva became the first long-acting HIV treatment to be approved by the FDA. This decision, in addition
0 Comments
Gene therapy has traditionally been applied to well-understood diseases where a single genetic mutation was to blame. A new generation of technology is expanding the potential of gene therapy to treat conditions that were previously unreachable.  Since the first gene therapy clinical trials in the 1990s, the technology has made its way into the market
0 Comments
A new platform makes automated western blot processing accessible to more labs, freeing up researchers’ valuable time, enabling the recovery of valuable antibodies for re-use, and providing consistent results blot after blot. Western blotting: an old but gold protein analysis technique Scientists first described the western blot procedure in 1979, and over the next four
0 Comments
Russia has established itself as a hub for neurotech startups, attracting scientists and business people keen to understand, treat, and repair the human brain. Here are the startups leading the charge of neurotech innovation in Russia.     Neurotechnology is a field of research that aims to read and influence the brain. Turns out that neurotech is
0 Comments
The first generation of vaccines for Covid-19 is rolling out all over the world. But are these vaccines able to withstand the force of viral evolution? The year 2021 has launched with a plethora of Covid-19 vaccines approved around the world. In Europe, candidates from AstraZeneca/University of Oxford, Moderna, and BioNTech/Pfizer are rolling out. The
0 Comments
Diego Miralles, M.D., has joined Flagship Pioneering as CEO-partner. Flagship disclosed the appointment of Miralles, who will serve as CEO of its portfolio company Laronde, alongside news that it has hired ex-Rubius Therapeutics executive Andrew Oh as senior partner.  Miralles joined Flagship after a three-year spell as CEO of Vividion Therapeutics, in which time he
0 Comments
Cancer biotech startup Penrose TherapeuTx is continuing its C-suite change-up by hiring oncology specialist Bhardwaj Desai, M.D., as its new chief development officer. Desai comes on board just a few months after the biotech hired Mark de Souza from cannabis company Revolution Global as its new chief executive. The biotech, which is working on next-gen
0 Comments
                Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Fraiser Kansteiner, and we will feature it here at the end of each week. After nabbing new CEO, Penrose TherapeuTx hires Pfizer, Astellas veteran chief development officer Penrose
0 Comments
Bristol Myers Squibb is putting down up to $1.3 billion on a next-gen engineered toxin body (ETB) cancer platform from Molecular Templates as it cuts an unwanted cell therapy from its Celgene buyout. The deal, heavily backloaded and worth just $70 million upfront with the rest in milestones, sees BMS tap Austin, Texas-based Molecular Templates’
0 Comments